Graphs on white board - ServicesImmuneering has more than a decade of experience providing critical work for major pharmaceutical companies helping them characterize drug mechanisms, identify targets, pinpoint biomarkers and more. Deploying in cloud-based or local environments, Immuneering analyzes clinical, laboratory and biobank data ranging from single-analyte to -omic level transcript, protein, genomics assays. Efficient and reusable code enables diving into biological signal, and we have spent years understanding how and why successful drugs work.

Immuneering is focused on rigorous and robust analysis which we maintain in analyzing gene expression and bioinformatic data. We deliver an iterative, feedback-driven approach and our methods are transparent with frequent interim updates to present results in meetings and/or written into reports showcase actionable insights. This has been showcased through multiple presentations, textbook chapters, patents and peer-reviewed publications. Over the past 12 years, Immuneering has worked with Janssen, Alexion, UCB, Rhythm, Teva, BMS, and Biogen to help their partners make the most of their data.

Case Studies

In partnership with Bristol-Myers Squibb, Immuneering helped BMS understand why only a certain group of patients with melanoma were responding to YERVOY. We detected gene expression in a subset of immune cells and were able to show that patients with that gene had an increased survival benefit. This work resulted in a new patent application (WO2014078468).

Learn More

In our continuing partnership with Janssen, Immuneering helped identify why subgroups of multiple myeloma (MM) patients treated with DARZALEX had different response profiles through discovering differential expression of T-cell co-stimulation proteins in better responding patients. This work resulted in several published abstracts and presentations at the American Society of Hematology.

Learn More

In partnership with Teva, Immuneering applied transcriptomics to characterize COPAXONE’s mechanism of action and compare it to potential generics, helping to ensure patient safety by providing new ways to more fully assess the biological impact of potential generics. This work resulted in several peer-reviewed publications.

Learn More